In a study of HER2-positive breast cancer patients who were treated with neoadjuvant Trastuzumab, gut α-diversity measures assessed before treatment showed significantly higher α-diversity in responders (n = 16) than in nonresponders (n = 7). This evidence concerns the gene ERBB2 and breast carcinoma.